Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
Oncolytics Biotech Inc. (NASDAQ: ONCY), a clinical-stage immunotherapy company, has announced its participation in two upcoming investment conferences in September 2024. Chief Financial Officer Kirk Look will attend the H.C. Wainwright 26th Annual Global Investment Conference on September 11, while Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in the 2024 Cantor Global Healthcare Conference on September 19.
Both executives will engage in fireside chats at their respective events in New York City. The company will also conduct one-on-one investor meetings during these conferences. Webcasts of the presentations will be available on Oncolytics' Investor Relations page and archived for three months.
Oncolytics Biotech Inc. (NASDAQ: ONCY), un'azienda di immunoterapia in fase clinica, ha annunciato la sua partecipazione a due conferenze sugli investimenti in programma per settembre 2024. Il Direttore Finanziario Kirk Look parteciperà al 26° Congresso Mondiale di Investimento H.C. Wainwright l'11 settembre, mentre Il Direttore Medico Tom Heineman, M.D., Ph.D., prenderà parte alla Conferenza Globale sulla Salute di Cantor 2024 il 19 settembre.
Entrambi i dirigenti parteciperanno a discussioni informali nei rispettivi eventi a New York. L'azienda condurrà anche incontri privati con gli investitori durante queste conferenze. Le trasmissioni video delle presentazioni saranno disponibili sulla pagina delle Relazioni con gli Investitori di Oncolytics e archiviate per tre mesi.
Oncolytics Biotech Inc. (NASDAQ: ONCY), una empresa de inmunoterapia en etapa clínica, ha anunciado su participación en dos próximas conferencias de inversión en septiembre de 2024. El Director Financiero Kirk Look asistirá a la 26ª Conferencia Global Anual de Inversión H.C. Wainwright el 11 de septiembre, mientras que El Director Médico Tom Heineman, M.D., Ph.D., participará en la Conferencia de Salud Global Cantor 2024 el 19 de septiembre.
Ambos ejecutivos participarán en charlas informales en sus respectivos eventos en la ciudad de Nueva York. La empresa también llevará a cabo reuniones individuales con inversores durante estas conferencias. Las transmisiones de las presentaciones estarán disponibles en la página de Relaciones con Inversores de Oncolytics y se archivarás por tres meses.
Oncolytics Biotech Inc. (NASDAQ: ONCY), 임상 단계의 면역 요법 회사는 2024년 9월에 예정된 두 개의 투자 컨퍼런스에 참여할 것이라고 발표했습니다. 최고 재무 책임자 Kirk Look은 9월 11일 H.C. Wainwright 제26회 글로벌 투자 컨퍼런스에 참석할 예정이며, 최고 의학 책임자 Tom Heineman, M.D., Ph.D.는 9월 19일 2024 Cantor 글로벌 헬스케어 컨퍼런스에 참여할 것입니다.
두 임원 모두 뉴욕시에서 각자의 행사에서 대화 세션에 참여할 것입니다. 회사는 이러한 컨퍼런스 동안 일대일 투자자 회의도 진행할 예정입니다. 프레젠테이션의 웹캐스트는 Oncolytics의 투자자 관계 페이지에서 제공되며 3개월 동안 아카이브됩니다.
Oncolytics Biotech Inc. (NASDAQ: ONCY), une entreprise d'immunothérapie en phase clinique, a annoncé sa participation à deux conférences d'investissement à venir en septembre 2024. Le directeur financier Kirk Look assistera à la 26e Conférence annuelle mondiale d'investissement H.C. Wainwright le 11 septembre, tandis que Le directeur médical Tom Heineman, M.D., Ph.D. participera à la Conférence mondiale de la santé Cantor 2024 le 19 septembre.
Les deux dirigeants participeront à des discussions informelles lors de leurs événements respectifs à New York. L'entreprise organisera également des réunions individuelles avec des investisseurs pendant ces conférences. Les webdiffusions des présentations seront disponibles sur la page des relations avec les investisseurs d'Oncolytics et archivées pendant trois mois.
Oncolytics Biotech Inc. (NASDAQ: ONCY), ein immuntherapie-unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Finanzvorstand Kirk Look wird am 11. September an der 26. Jährlichen Globale Investorenkonferenz von H.C. Wainwright teilnehmen, während Chefarzt Tom Heineman, M.D., Ph.D., am 19. September an der 2024 Cantor Global Healthcare Conference teilnimmt.
Beide Führungskräfte werden bei ihren jeweiligen Veranstaltungen in New York City an informellen Gesprächen teilnehmen. Das Unternehmen wird auch Einzelgespräche mit Investoren während dieser Konferenzen führen. Die Webcasts der Präsentationen werden auf der Investor-Relations-Seite von Oncolytics verfügbar sein und drei Monate lang archiviert werden.
- None.
- None.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, Holmes I Room - 4th Floor
Webcast Link: Available by clicking here
Event: Cantor 2024 Global Healthcare Conference
Date: Thursday, September 19, 2024
Time: 10:55 a.m. ET
Location: InterContinental New York Barclay Hotel, Track 6 Morgan Suite
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Cantor Fitzgerald representative, or email jpatton@oncolytics.ca.
Webcasts of the Company's presentations will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Logo : https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-fireside-chats-at-two-investment-conferences-in-september-302240554.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When and where will Oncolytics Biotech (ONCY) participate in investment conferences in September 2024?
Who will represent Oncolytics Biotech (ONCY) at the September 2024 investment conferences?
How can investors access the webcasts of Oncolytics Biotech's (ONCY) presentations at the September 2024 conferences?
Will Oncolytics Biotech (ONCY) offer one-on-one investor meetings during the September 2024 conferences?
